Selected CYP1A2 Substrates/Vemurafenib
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Vemurafenib can slow the breakdown of some medications such as tizanidine, clozapine, theophylline or tacrine.
What might happen:
If the blood level of your medicine increases you may have an increase in side effects.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
References:
1.Zelboraf (vemurafenib) US Prescribing Information. Hoffman-La Roche August, 2011.
2.Azilect (rasagiline) US prescribing information. Teva Neurosciences Inc. December, 2009.
3.Valdoxan (agomelatine) UK summary of product characteristics. Les Laboratoires Servier February 19, 2009.





